Ron Baker - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Role
Chief Business Officer
Signature
/s/ Ron Baker
Issuer symbol
N/A
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
3
Filing time
17 Feb 2026, 18:29:15 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Baker Ron Chief Business Officer C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG /s/ Ron Baker 17 Feb 2026 0002109536

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding Stock Option 17 Feb 2026 Common Stock 50,000 $1.74 Direct F1
holding Stock Option 17 Feb 2026 Common Stock 25,000 $2.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 50,000 shares of common stock, with 25,000 shares vested on the date of the grant and the remaining shares vested in equal monthly installments over the following 24 months.
F2 On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 25,000 shares of common stock, with 6,250 shares vesting on the date of grant and the remaining shares vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.